This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
13 Apr 2011

Pieris Inks €207M Discovery Deal with Daiichi Sankyo

The companies signed a collaboration and license agreement under which Pieris will use its Anticalin scaffold technology against two targets to be provided by Daiichi Sankyo.

Germany's Pieris AG has signed a drug discovery pact with Japan's Daiichi Sankyo. The contract will offer more than €7 million in an upfront payment and up to €200 million in fees, research funding and milestones. In the deal Pieris will use of its drug development platform to find two new drugs that can hit Daiichi Sankyo's targets.

 

"Our deal with Daiichi Sankyo demonstrates yet again the high value of the Anticalin technology and we're extremely proud to count Daiichi Sankyo among the growing list of industry leaders who are our

Related News